Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Trial of M7824 in Solid Tumors With Microsatellite Instability With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer in Combination With Radiation, or in Colorectal Cancer Patients With Detectable Circulating Tumor DNA Following Definitive Therapy

Trial Profile

A Phase Ib/II Trial of M7824 in Solid Tumors With Microsatellite Instability With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer in Combination With Radiation, or in Colorectal Cancer Patients With Detectable Circulating Tumor DNA Following Definitive Therapy

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bintrafusp alfa (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colon cancer; Colorectal cancer; Rectal cancer; Solid tumours
  • Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 31 May 2020 as reported in an abstract presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2020 Status changed from recruiting to discontinued, as reported in an abstract presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2020 Results assessing consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer patients presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top